$5 million represents STAAR's highest quarterly ICL sales in U.S. since it obtained FDA approval for EVO ICL in March 2022. Analyst says achieving STAAR Surgical's revenue target for 2026 seems ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, ...

Agreement is Largest Commitment to EVO ICL™ in the U.S. LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of ...

“EVO ICL is the next logical step in refractive innovation. While adoption of any new technology takes time, EVO ICL’s adoption rate has been steadily rising since launch – achieving market leadership ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Thanks to recent technological improvements, the ICL could take the place at the forefront of vision ...

Please provide your email address to receive an email when new articles are posted on . Trattler shared a case in which a high myope with keratoconus experienced improvements in visual acuity and ...

(RTTNews) - STAAR Surgical Company (STAA) Tuesday announced partnership with ophthalmology group, SharpeVision to provide EVO ICL lenses to all qualified patients in SharpeVision clinics. STAAR ...

On Tuesday, Staar Surgical Company (NASDAQ:STAA) reported a fourth-quarter 2024 EPS loss of 69 cents, a turnaround from an income of 16 cents, missing the consensus loss of 16 cents. The contact lens ...

GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)-- Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (STAA) (“STAAR”), the manufacturer of ...

The center is equipped with microscopes and wet lab situations Staar Surgical Co. last month unveiled the new location of its company-owned ophthalmology training center. The eye lens maker moved the ...